Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 05ANKARA394, GOT's New Data Exclusivity Regulation - Major

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #05ANKARA394.
Reference ID Created Released Classification Origin
05ANKARA394 2005-01-25 15:35 2011-08-24 01:00 UNCLASSIFIED//FOR OFFICIAL USE ONLY Embassy Ankara
This record is a partial extract of the original cable. The full text of the original cable is not available.
UNCLAS SECTION 01 OF 02 ANKARA 000394 
 
SIPDIS 
 
DEPT FOR E, EB/TPP/MTA/IPC, EUR/ERA, EUR/SE 
USTR FOR LERRION/BPECK 
USEU FOR CHRIS WILSON 
USPTO FOR ELAINE WU 
USDOC FOR ITA/MAC/DDEFALCO 
 
SENSITIVE 
 
E.O. 12958: N/A 
TAGS: ETRD KIPR TU
SUBJECT:  GOT's New Data Exclusivity Regulation - Major 
Gaps in Protection 
 
 
SENSITIVE BUT UNCLASSIFIED.  PLEASE HANDLE ACCORDINGLY. 
 
1. (SBU) Summary:  The GOT issued a revised regulation 
on January 19 providing a six-year term of data 
exclusivity protection for confidential pharmaceuticals 
test data effective January 1, 2005.  The regulation 
contains major loopholes, including lack of 
retroactivity and other provisions which effectively 
whittle down the six-year term.  The European Commission 
is evaluating Turkey's regulation in the context of its 
Trade Barrier Review (TBR) on barriers in the 
pharmaceuticals sector.  Research-based industry is also 
meeting to consider next steps.  End Summary. 
 
2. (U) On January 19, the GOT announced its long-awaited 
policy on data exclusivity by publishing a revised 
pharmaceuticals marketing regulation in the State 
Gazette.  Based on a preliminary review of the 
regulation (see para for 5 a translation provided by 
Pfizer) and comments by one U.S. company, the policy 
seems similar to earlier, unsatisfactory drafts on data 
exclusivity.  The regulation provides a six-year term of 
data exclusivity protection beginning on January 1, 
2005, and in certain cases, beginning in 2001, but with 
exceptions that could reduce its benefits to research- 
based companies.  These include: 
 
-- Starting the six-year term on the date of licensing 
in an EU Customs Union country.  According to Pfizer, 
this provision cuts the effective term of protection 
because it can take over 200 days for a drug to go 
through the marketing approval process in Turkey; 
 
-- Limiting the term of data exclusivity to the term of 
the drug's patent in Turkey.  Note:  A Pfizer 
representative told us that this is unhelpful, but not 
inconsistent with existing EU regulations.  End Note; 
 
-- Original products licensed in a Customs Union country 
after January 1, 2001 can enjoy data exclusivity 
protection, unless generics manufacturers have applied 
for licenses in Turkey prior to 2005.  According to U.S. 
industry, there are hundreds, and possibly over 1,000 
pending applications in this category at the Ministry of 
Health.  With this vast loophole, relatively few drugs 
launched prior to 2005 will be able to benefit from data 
exclusivity protection. 
 
3. (SBU) An EU diplomat told us that the GOT had 
provided no advance notice to Brussels of this 
regulation, despite the fact that the European 
Commission had raised data exclusivity and other 
pharmaceuticals concerns with the Turks in writing 
through the TBR process.  She told Econoff that Brussels 
would evaluate the regulation in meetings later this 
week. 
 
4. (SBU) Comment and Recommendation:  It appears that 
the new GOT regulation falls far short of a satisfactory 
solution to our concerns on data exclusivity, and that 
this issue, along with patent linkage, will be leading 
subjects in the upcoming Special 301 review of Turkey. 
Although the EU declined an earlier U.S. request to do a 
joint demarche on this subject to the Turks, the time 
may be ripe for another approach to Brussels.  We 
recommend that Washington agencies consider the merits 
of a joint demarche, and, if appropriate, provide 
guidance to the Embassy and to USEU. 
 
5. (U) Begin Text Pfizer Translation - Registration 
Regulation Article 9/Temporary Article 1: 
 
Article 9- Without prejudice to the provisions of the 
Decree Law dated 24/06/1995,with no. 551, on the 
Protection of Patent Rights; 
a) In abridged applications, the applicant shall not be 
required to present the results of toxicological and 
pharmacological tests and clinical trials, provided that 
one of the following points is proved: 
1) The medicinal product shall be mostly similar to a 
medicinal product which previously registered in Turkey 
and the marketing registration holder of the original 
medicinal product shall have consented to the use of the 
toxicological, pharmacological and/or clinical 
references contained in the dossier of the original 
medicinal product for the purpose of evaluating the 
referred application, 
2) Any constituent(s) of the medicinal product shall 
have a well-established medical use, determined by means 
of detailed scientific bibliography and with a 
reasonable efficiency and acceptable level of 
reliability, 
3) The medicinal product shall be essentially similar 
with a medicinal product which has been registered in 
accordance with the current legislative provisions and 
has completed its data exclusivity period. The data 
exclusivity period called for by this subparagraph, 
shall apply on the original products for which no 
generic registration application has been submitted in 
Turkey until 01/01/2005, among the original products 
registered for the first time after 01/01/2001 in one of 
the countries within the Customs Union Area and the 
original products to be registered for the time after 
01/01/2005 in one of the countries of the Customs Union 
Area and shall be 6 (six) years to begin as of the first 
registration date in the Customs Union Area and to be 
limited with the patent period of the  relevant molecule 
in Turkey. 
However, in the event of a different therapeutical 
indication, route of administration, dosage being 
envisaged from those of the medicinal products which 
have been introduced into the market, it shall be 
necessary to submit the results of the relevant clinical 
trials and where necessary the results of toxicological, 
pharmacological studies. 
b) With regard to new medicinal products containing 
recognized constituents, but which have not yet been 
used in combination for therapeutical purposes, it shall 
be necessary to present the results of the relevant 
toxicological and pharmacological tests and clinical 
trials. However, it shall not be obligatory to present 
the references pertaining to each constituent. 
In compliance with subparagraph (2) in item (a) of the 
first paragraph of this article, in the event of the 
presentation of bibliographical references based on 
published data, the applications shall be submitted in 
accordance with Annex I. 
In exceptional cases constituting a severe threat for 
public health, the Ministry may take into consideration 
the registration applications of generic products, which 
have been presented upon taking as basis the data 
pertaining to the toxicological, pharmacological and 
clinical data published on literature, independent from 
the provisions set forth in this article. 
 
Temporary Article 1- The registration/permit 
applications submitted before the enforcement of this 
Regulation, shall be evaluated in accordance with the 
legislative provisions in force on the date such 
applications are submitted. 
With regard to the abridged applications presented in 
accordance with article 9 of this Regulation of which 
all provisions except for article 9 shall be enforced on 
30/06/2005, the applications submitted in compliance 
with the application format indicated in the Regulation 
in force shall be accepted. 
 
End Text Pfizer Translation. 
 
Edelman